Table III.
HRs associated with the combined NUG in the Hippo pathway genes in CM patients
| NUG† | No.
|
Univariate analysis
|
Multivariate analysis*
|
|||
|---|---|---|---|---|---|---|
| Patients | Death (%) | HR (95% CI) | P | HR (95% CI) | P | |
| 0 | 216 | 9 (4.17) | 1 | 1 | ||
| 1 | 395 | 48 (12.15) | 3.07 (1.50–6.25) | 0.002 | 2.88 (1.40–5.93) | 0.004 |
| 2 | 204 | 32 (15.69) | 4.01 (1.91–8.40) | <0.001 | 4.16 (1.97–8.79) | <0.001 |
| 3 | 43 | 6 (13.95) | 3.44 (1.22–9.67) | 0.019 | 5.89 (2.07–16.77) | <0.001 |
| Trend | P < 0.001 | P < 0.001 | ||||
| 0 | 216 | 9 (4.17) | 1 | 1 | ||
| 1 | 395 | 48 (12.15) | 3.06 (1.50–6.24) | 0.003 | 2.89 (1.40–5.93) | 0.004 |
| 2–3 | 247 | 38 (15.38) | 3.91 (1.89–8.08) | <0.001 | 4.37 (2.10–9.11) | <0.001 |
| Trend | P < 0.001 | P < 0.001 | ||||
| 0 | 216 | 9 (4.17) | 1 | 1 | ||
| 1–3 | 642 | 86 (13.40) | 3.39 (1.71–6.73) | <0.001 | 3.41 (1.70–6.81) | <0.001 |
NUG = number of unfavorable genotype; CM = cutaneous melanoma.
†
Number of unfavorable genotypes (NUG) included rs11225163 CC, rs7944031 AG/GG, and rs1990330 CA/AA.
*
Adjusted by age, sex, tumor stage, Breslow thickness, SLNB, Clark level, ulceration of tumor and tumor cell mitotic rate.